Regentis Biomaterials completes $10 million initial public offering

Regentis Biomaterials Ltd. (NYSE American: RGNT) completed its initial public offering of 1,250,000 ordinary shares at $8.00 per share, generating gross proceeds of $10 million before underwriting discounts and expenses, according to a company statement.

The Israel-based regenerative medicine company's shares began trading on the NYSE American on December 4, 2025, under the ticker symbol "RGNT." The company also granted underwriters a 45-day option to purchase up to 187,500 additional shares to cover over-allotments.

Regentis plans to use the net proceeds primarily for development activities, including completion of its pivotal trial and preparation of a PMA submission for GelrinC, its lead product candidate. The funds will also support corporate purposes including debt repayment and deferred compensation payments.

ThinkEquity served as the sole book-running manager for the offering. The company's registration statement on Form F-1 became effective with the Securities and Exchange Commission on November 12, 2025.

Regentis develops tissue repair solutions using its Gelrin platform based on degradable hydrogel implants. GelrinC is designed as a cell-free, off-the-shelf hydrogel treatment for painful articular knee cartilage injuries. The product received CE mark approval in Europe and the company plans to begin commercialization efforts there while pursuing FDA approval in the United States.

You May Also Be Interested In